KTTA vs. RNAZ, VCNX, IBIO, ALZN, AIM, PMCB, TLPH, AYTU, TSBX, and CARA
Should you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include TransCode Therapeutics (RNAZ), Vaccinex (VCNX), iBio (IBIO), Alzamend Neuro (ALZN), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Talphera (TLPH), Aytu BioPharma (AYTU), Turnstone Biologics (TSBX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry.
TransCode Therapeutics (NASDAQ:RNAZ) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
TransCode Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Pasithea Therapeutics' return on equity of -74.56% beat TransCode Therapeutics' return on equity.
23.9% of Pasithea Therapeutics shares are held by institutional investors. 1.5% of TransCode Therapeutics shares are held by company insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
TransCode Therapeutics received 8 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 90.91% of users gave TransCode Therapeutics an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote.
Pasithea Therapeutics has higher revenue and earnings than TransCode Therapeutics.
In the previous week, TransCode Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for TransCode Therapeutics and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.96 beat TransCode Therapeutics' score of 0.03 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.
TransCode Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 1,032.50%. Given TransCode Therapeutics' higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Pasithea Therapeutics.
Summary
Pasithea Therapeutics beats TransCode Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Pasithea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pasithea Therapeutics Competitors List
Related Companies and Tools
Free KTTA Stock Alerts